-
RAPT Therpaeutics NASDAQ:RAPT RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.
Location: 561 Eccles Ave, California, 94080-1906, US | Website: www.rapt.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-49.09M
Cash
97.91M
Avg Qtr Burn
-25.15M
Short % of Float
16.60%
Insider Ownership
0.49%
Institutional Own.
96.43%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Zelnecirnon / RPT193 (CCR4 antagonist) Details Atopic dermatitis | Phase 2b Update | |
Tivumecirnon / FLX475 (CCR4 antagonist) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 2 Data readout | |
Zelnecirnon/ RPT193 (CCR4 antagonist) Details Asthma, Lung disease | Phase 2a Update |